Hamzaoui K, Hamzaoui A, Zakraoui L, Chabbou A
Immunohistology Laboratory, Medicine University of Tunis, Tunisia.
Mediators Inflamm. 1998;7(2):111-4. doi: 10.1080/09629359891261.
The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.
本研究旨在对处于活动期和非活动期的白塞病（BD）患者血清中的可溶性Fas/APO-1（sFas/APO-1）蛋白进行定量，并与系统性红斑狼疮（SLE）患者和类风湿关节炎（RA）患者进行比较。采用夹心酶联免疫吸附测定法对可溶性Fas/APO-1进行定量。与非活动期BD、RA患者和SLE患者相比，活动期BD患者血清sFas/APO-1水平升高。活动期BD患者血清sFas/APO-1水平升高与神经系统表现或肺部受累有关。总之，sFas/APO-1水平升高在活动期BD患者中频繁且仅出现。初步证据表明，BD患者sFas/APO-1水平升高与临床分期及临床表现相关。
